- Home
- FAX vs QURE Comparison
FAX vs QURE Comparison
Compare FAX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAX
- QURE
- Stock Information
- Founded
- FAX 1986
- QURE 1998
- Country
- FAX United States
- QURE Netherlands
- Employees
- FAX N/A
- QURE N/A
- Industry
- FAX Investment Managers
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- FAX Finance
- QURE Health Care
- Exchange
- FAX Nasdaq
- QURE Nasdaq
- Market Cap
- FAX 629.1M
- QURE 691.2M
- IPO Year
- FAX N/A
- QURE 2007
- Fundamental
- Price
- FAX $15.71
- QURE $12.84
- Analyst Decision
- FAX
- QURE Strong Buy
- Analyst Count
- FAX 0
- QURE 8
- Target Price
- FAX N/A
- QURE $39.43
- AVG Volume (30 Days)
- FAX 833.6K
- QURE 820.4K
- Earning Date
- FAX 01-01-0001
- QURE 03-03-2025
- Dividend Yield
- FAX 12.09%
- QURE N/A
- EPS Growth
- FAX N/A
- QURE N/A
- EPS
- FAX N/A
- QURE N/A
- Revenue
- FAX N/A
- QURE $28,587,000.00
- Revenue This Year
- FAX N/A
- QURE $153.92
- Revenue Next Year
- FAX N/A
- QURE N/A
- P/E Ratio
- FAX N/A
- QURE N/A
- Revenue Growth
- FAX N/A
- QURE N/A
- 52 Week Low
- FAX $2.33
- QURE $3.73
- 52 Week High
- FAX $2.84
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- FAX 59.10
- QURE 38.20
- Support Level
- FAX $15.38
- QURE $12.72
- Resistance Level
- FAX $15.91
- QURE $14.42
- Average True Range (ATR)
- FAX 0.14
- QURE 0.85
- MACD
- FAX 0.03
- QURE -0.26
- Stochastic Oscillator
- FAX 62.45
- QURE 7.26
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities, and others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.